A Phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma
Refereed conference paper presented and published in conference proceedings

Full Text

Other information
All Author(s) ListLIM Ho Yeong, YEN Chia Jui, TAK Won Young, HEO Jeong, CHOI Hye Jin, LIN Cheng Yao, YOON Jung Hwan, HSU Chiun, RAU Kun Ming, POON Ronnie, YEO Winnie, PARK Joong Won, TAY Miah Hiang, HSIEH Wen Son, KAPPELER Christian, RAJAGOPALAN Prabhu, KRISSEL Heiko
Name of ConferenceAnnual Meeting of the American Society of Clinical Oncology
Start Date of Conference01/06/2012
Country/Region of ConferenceUnited States of America
Proceedings TitleAnnual Meeting of the American Society of Clinical Oncology
Place of PublicationUnited States of America
LanguagesEnglish-United Kingdom
Keywordsunresectable hepatocellular carcinoma

Last updated on 2018-20-01 at 07:36